Jia Wei

This paper develops a PD-1-iRGD conjugate that enhances antitumor efficacy by improving T cell engagement and penetration, and expands a unique population of CD8+ T cells in the tumor microenvironment.

This study identifies GFPT2 as a metabolic checkpoint in EGFR-mutated NSCLC that promotes immune evasion, and shows that targeting GFPT2 enhances PD-1 blockade therapy.